L. Swinnen

发表

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study.

R. Advani, R. Gascoyne, S. Horning, 2010, Blood.

Epstein-Barr Virus (EBV) DNA in Plasma Is Not Encapsidated in Patients With EBV-Related Malignancies

M. Gulley, S. Schichman, N. Raab-Traub, 2004, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Geographically distinct HHV-8 DNA sequences in Saudi Arabian Iatrogenic Kaposi's sarcoma lesions.

S. Alkan, L. Swinnen, B. Nickoloff, 1998, The American journal of pathology.

Thrombotic Microangiopathy After Post-Transplantation Cyclophosphamide-Based GVHD Prophylaxis.

R. Varadhan, C. Huff, Richard J. Jones, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide.

G. Rosner, C. Huff, M. Zahurak, 2017, Blood advances.

Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.

S. Rosenfeld, D. Macdonald, D. Ramsay, 2000, Neuro-oncology.

O6-Methylguanine-DNA Methyltransferase in Tumors and Cells of the Oligodendrocyte Lineage

J. Cairncross, J. Costello, C. Nutt, 1995, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05)

R. Advani, D. Moore, D. Schiff, 2017, Oncotarget.

Non-Hodgkin's lymphomas, version 4.2014.

J. Byrd, R. Advani, J. Vose, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis.

Q. Tao, G. Srivastava, K. Robertson, 1999, The American journal of pathology.

BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders.

P. Murray, L. Swinnen, R. Ambinder, 1996, Blood.

Severe cytokine release syndrome after haploidentical peripheral blood transplantation.

C. Huff, Richard J. Jones, D. Gladstone, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy

R. Wahl, L. Swinnen, Y. Kasamon, 2004, Current opinion in oncology.

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.

T. Habermann, Richard J. Jones, J. Herman, 2012, Blood.

Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia

Steve Y. Cho, C. Huff, M. Borowitz, 2013, Leukemia & lymphoma.

Central nervous system cancers, version 1.2017 featured updates to the NCCN guidelines

P. Wen, N. Butowski, M. Mrugala, 2017 .

Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma.

M. Mrugala, T. Kaley, C. Grommes, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Lung transplantation for advanced bronchioloalveolar carcinoma confined to the lungs.

L. Swinnen, A. Montoya, E. Garrity, 2000, Transplantation.

Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.

R. Gascoyne, T. Habermann, J. Krauss, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial

Sonali M. Smith, J. Friedberg, L. Swinnen, 2017, Leukemia & lymphoma.

Frequent expression of the tumor necrosis factor receptor-associated factor 1 in latent membrane protein 1-positive posttransplant lymphoproliferative disease and HIV-associated lymphomas.

M. Gulley, L. Young, J. Flavell, 2001, Human pathology.

Simian virus 40 is present in most United States human mesotheliomas, but it is rarely present in non-Hodgkin's lymphoma.

R. Fisher, H. Pass, S. Fisher, 1999, Chest.

Early treatment intensification for aggressive non-Hodgkin's lymphoma.

L. Swinnen, 2006, Current opinion in oncology.

Durable remission after aggressive chemotherapy for post-cardiac transplant lymphoproliferation.

L. Swinnen, 1997, Leukemia & lymphoma.

Non-Hodgkin's Lymphomas, version 3.2012.

J. Byrd, R. Advani, J. Vose, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Post‐transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities

Sonali M. Smith, M. L. Le Beau, L. Swinnen, 2006, Genes, chromosomes & cancer.

A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.

L. Recht, S. Phuphanich, M. Chamberlain, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Organ transplant-related lymphoma

L. Swinnen, 2001, Current treatment options in oncology.

Non-Hodgkin's lymphomas, version 2.2014.

J. Byrd, R. Advani, J. Vose, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

J. Byrd, R. Advani, J. Vose, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels

I. Flinn, R. Wahl, S. Piantadosi, 2021, Cancers.

Non-Hodgkin’s Lymphomas, Version 4.2014: Clinical Practice Guidelines in Oncology

J. Byrd, R. Advani, J. Vose, 2014 .

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

J. Byrd, R. Advani, J. Vose, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia

Richard J. Jones, C. Griffin, D. Gladstone, 2011, Leukemia & lymphoma.

A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149)

C. Rankin, K. Albain, H. Carraway, 2008, Journal of Neuro-Oncology.

Epstein-barr virus-induced posttransplant lymphoproliferative disorders

E. Kieff, T. Habermann, G. Gores, 1999 .

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.

R. Varadhan, C. Huff, M. Perales, 2023, The New England journal of medicine.

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide.

Richard J. Jones, M. Levis, D. Gladstone, 2018, Blood advances.

Treatment advances in adult Burkitt lymphoma and leukemia

L. Swinnen, Y. Kasamon, 2004, Current opinion in oncology.

Non-Hodgkin's lymphomas, version 1.2013.

J. Byrd, R. Advani, J. Vose, 2013, The Journal of the National Comprehensive Cancer Network.

TREATMENT OF ORGAN LYMPHOMA TRANSPLANT-RELATED

L. Swinnen, 1997 .

Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide.

C. Huff, L. Gondek, Richard J. Jones, 2020, Blood advances.

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.

R. Advani, J. Vose, L. Gordon, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma

R. Varadhan, M. Borowitz, Richard J. Jones, 2019, Leukemia & lymphoma.

OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation.

R. Fisher, L. Swinnen, R. I. Fisher, 1993, Current opinion in nephrology and hypertension.

Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial

J. Manola, R. Advani, T. Habermann, 2012, Leukemia & lymphoma.

Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.

S. Phuphanich, T. Batchelor, M. Chamberlain, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model

K. Albain, L. Swinnen, P. Stiff, 2004, Cancer Chemotherapy and Pharmacology.

Sensitization of Resistant Human Tumor Cells to Cisplatin or Carboplatin by Inhibitors of DNA Excision Repair

L. Swinnen, L. Erickson, N. K. Ellis, 1991 .

Characterization of postcardiac transplant lymphomas. Histology, immunophenotyping, immunohistochemistry, and gene rearrangement.

L. Swinnen, G. Dizikes, J. Pyle, 1996, Archives of pathology & laboratory medicine.

Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma

M. Borowitz, Richard J. Jones, J. Bolaños-Meade, 2013, Leukemia & lymphoma.

Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide.

G. Rosner, C. Huff, M. Zahurak, 2020, Blood advances.

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.

R. Varadhan, C. Huff, M. Zahurak, 2017, Blood.

Epstein-Barr virus (EBV) variant with a 30-bp deletion at the carboxyl terminus (amino acids 346-355) of latent membrane protein-1 (LMP1) gene is able to transform cells and evade immune surveillance.

Q. Tao, L. Swinnen, R. Ambinder, 1998, The American journal of pathology.

Increasing the dose of total body irradiation to decrease graft failure associated with HLA-haploidenticaltransplantation for patients with severe hemoglobinopathies. A single institution prospective clinical trial

C. Huff, Richard J. Jones, D. Gladstone, 2019 .

The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.

Richard J. Jones, C. Griffin, D. Gladstone, 2012, Clinical lymphoma, myeloma & leukemia.

Cytomegalovirus infections in heart transplant recipients: relationship to immunosuppression.

S. Fisher, L. Swinnen, M. Johnson, 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma (cHL).

T. Habermann, L. Swinnen, H. Jacene, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-Dose Cyclophosphamide (Cy), Rituximab, and a Cancer Vaccine for Relapsed Classical Hodgkin's Lymphoma (cHL)

M. Borowitz, Richard J. Jones, L. Swinnen, 2010 .

Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404

R. Advani, R. Gascoyne, S. Horning, 2008 .

High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.

L. Deangelis, J. Cairncross, S. Rosenfeld, 2006, Neuro-oncology.

High-dose Chemotherapy with Stem Cell Rescue as Initial Therapy for Anaplastic Oligodendroglioma

L. Deangelis, J. Cairncross, S. Rosenfeld, 2003, Journal of Neuro-Oncology.

Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.

S. Rosenfeld, D. Macdonald, D. Ramsay, 2000, Neuro-oncology.

Burkitt's lymphoma and Hodgkin's disease CpG methylation of the major Epstein-Barr virus latency promoter in

M. Gulley, K. Robertson, L. Swinnen, 2009 .

Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811).

G. Barger, C. Rankin, E. Rushing, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients

M. Zahurak, D. Gladstone, L. Swinnen, 2018, Cancer Chemotherapy and Pharmacology.

An Open Label Trial of Sustained-release Cytarabine (DepoCyt™) for the Intrathecal Treatment of Solid Tumor Neoplastic Meningitis

M. Gilbert, W. Mason, E. Wong, 2004, Journal of Neuro-Oncology.

High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas

I. Flinn, C. Huff, M. Zahurak, 2011, Leukemia & lymphoma.

l-/3-D-Arabinofuranosylcytosine and Hydroxyurea Production of Cytotoxic Synergy with cis-Diamminedichloroplatinum(II) and Modification of Platinum-induced DNA Interstrand Cross-Linking1

R. Fisher, K. Albain, D. Barnes, 2006 .

Posttransplant Lymphoproliferative Disorder

L. Swinnen, 2000 .

Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders.

L. Swinnen, 2006, Best practice & research. Clinical haematology.

Post-transplant lymphoproliferative disorders: implications for acquired immunodeficiency syndrome-associated malignancies.

L. Swinnen, 2000, Journal of the National Cancer Institute. Monographs.

NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines

J. Byrd, R. Advani, J. Vose, 2017 .

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.

J. Byrd, R. Advani, J. Vose, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

EBV-specific T-cell therapy

L. Swinnen, 2007 .

Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)

Y. Natkunam, R. Advani, R. Gascoyne, 2014, Leukemia & lymphoma.

Conservation of Epstein-Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy.

Q. Tao, Jie Yang, L. Swinnen, 2002, The American journal of pathology.

Transplant immunosuppression-related malignant lymphomas.

L. Swinnen, 1993, Cancer treatment and research.

Post-Transplantation Lymphoproliferative Disorder

L. Swinnen, 1992 .

Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder

Alan M. Miller, L. Gordon, R. Fisher, 2008, Transplantation.

Epstein–Barr viral load as a marker of lymphoma in AIDS patients

M. Gulley, P. Eagan, S. Schichman, 2005, Journal of medical virology.

Overview of posttransplant B-cell lymphoproliferative disorders.

L. Swinnen, 1999, Seminars in oncology.

Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation.

Brian S. Iglehart, C. Huff, Richard J. Jones, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.1

T. Grogan, M. Gulley, L. Swinnen, 2003, Transplantation.

Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine

L. Recht, M. Gilbert, W. Mason, 2001, British Journal of Cancer.

Analytic Validation of a Competitive Polymerase Chain Reaction Assay for Measuring Epstein-Barr Viral Load

M. Gulley, P. Eagan, S. Schichman, 2001, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults.

Elias T. Zambidis, Allen R. Chen, M. Zahurak, 2020, Blood advances.

Association of Human Leukocyte Antigen Haplotypes with Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation

E. González-Barca, R. Hetzer, H. Riess, 2006, Transplantation.

Donor‐Transmitted Malignancies in Organ Transplantation: Assessment of Clinical Risk

J. DiMaio, M. Ison, L. Swinnen, 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Non-Hodgkin's Lymphomas, version 3.2012: Featured updates to the NCCN guidelines

J. Byrd, R. Advani, J. Vose, 2012 .

Outcomes of Allogeneic Blood or Marrow Transplantation for Peripheral T-Cell Lymphoma.

Richard J. Jones, D. Gladstone, L. Swinnen, 2012 .

Non-Hodgkin's lymphomas, version 1.2013.

J. Byrd, R. Advani, J. Vose, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

P. Wen, N. Butowski, M. Mrugala, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Non-Hodgkin's LymphomasPractice Guidelines in Oncology TM

J. Byrd, R. Advani, J. Vose, 2010 .

NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.

P. Wen, N. Butowski, M. Mrugala, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70.

R. Varadhan, C. Huff, Richard J. Jones, 2019, Blood advances.

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Central Nervous System Cancers, Version 3.2020

er, P. Wen, N. Butowski, 2020 .

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

C. Flowers, S. de Vos, L. Swinnen, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Posttransplantation Cyclophosphamide-based Graft versus Host Disease Prophylaxis with Non-myeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis.

R. Varadhan, C. Huff, L. Gondek, 2022, Transplantation and cellular therapy.

Diagnosis and treatment of transplant-related lymphoma.

L. Swinnen, Lode J. Swinnen, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of organ transplant-related lymphoma.

L. Swinnen, 1997, Hematology/oncology clinics of North America.

Increased risk of lymphoproliferative disorders following the use of OKT3: Association with cumulative dose

L. Swinnen, 1996 .

Aggressive treatment for postcardiac transplant lymphoproliferation.

R. Fisher, L. Swinnen, M. Costanzo, 1995, Blood.

Mucosa-associated lymphoid tissue-type lymphomas occurring in post-transplantation patients.

S. Alkan, T. Singleton, L. Swinnen, 2000, The American journal of surgical pathology.

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide

Shannon R. McCurdy, G. Rosner, C. Huff, 2017, Haematologica.

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

Shannon R. McCurdy, G. Rosner, C. Huff, 2015, Blood.

Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation1

L. Swinnen, D. Hanto, M. McBride, 2003, Transplantation.

Transplantation-related lymphoproliferative disorder: a model for human immunodeficiency virus-related lymphomas.

L. Swinnen, 2000, Seminars in oncology.

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

J. Byrd, R. Advani, J. Vose, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy.

R. Varadhan, Richard J. Jones, L. Swinnen, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience.

R. Varadhan, C. Huff, L. Gondek, 2021, Clinical lymphoma, myeloma & leukemia.

Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.

C. Huff, J. Kowalski, Richard J. Jones, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.

C. Huff, Richard J. Jones, D. Gladstone, 2019, The Lancet. Haematology.

Shortened-duration immunosuppressive therapy after nonmyeloablative, related HLA-haploidentical or unrelated peripheral blood grafts and post-transplantation cyclophosphamide.

G. Rosner, C. Huff, M. Zahurak, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.

G. Rosner, C. Huff, M. Zahurak, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors.

Shannon R. McCurdy, G. Rosner, C. Huff, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.

I. Flinn, C. Huff, Richard J. Jones, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.

Shannon R. McCurdy, G. Rosner, C. Huff, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.

C. Huff, Richard J. Jones, D. Gladstone, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nonmyeloablative, HLA-mismatched unrelated peripheral blood transplantation with high-dose posttransplantation cyclophosphamide.

C. Huff, M. Zahurak, Richard J. Jones, 2021, Transplantation and cellular therapy.

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

G. Rosner, C. Huff, M. McDevitt, 2014, Blood.

Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes.

Shannon R. McCurdy, R. Varadhan, C. Huff, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Richard J. Jones, D. Gladstone, J. Bolaños-Meade, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: a Retrospective Cohort Study.

R. Varadhan, M. Zahurak, Richard J. Jones, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide.

Shannon R. McCurdy, G. Rosner, C. Huff, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Blood or Marrow Transplantation with High-Dose Post-transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Aged ≥55.

R. Varadhan, C. Huff, C. Hourigan, 2022, Transplantation and cellular therapy.

Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplant Cyclophosphamide in Chronic Lymphocytic Leukemia.

R. Varadhan, Richard J. Jones, D. Gladstone, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.

R. Varadhan, C. Huff, Richard J. Jones, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes Of Nonmyeloablative (NMA) Haploidentical Blood Or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy) For Lymphoma

Richard J. Jones, D. Gladstone, J. Bolaños-Meade, 2013 .

Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide

G. Rosner, C. Huff, M. Zahurak, 2016, Leukemia & lymphoma.

Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.

Sonali M. Smith, J. Friedberg, J. Leonard, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.

P. Wen, N. Butowski, M. Mrugala, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.

R. Advani, J. Vose, L. Gordon, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.

G. Rosner, C. Huff, Richard J. Jones, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study.

T. Fleming, P. Goodman, E. Hersh, 1990, Journal of biological response modifiers.

Central Nervous System Cancers, Version 1.2015.

Stephanie Weiss, Henry Brem, Lawrence Recht, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines.

L. Recht, A. Friedman, M. Gilbert, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage

P. Burger, M. Borowitz, L. Swinnen, 2015, Oncotarget.

White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab

D. Gladstone, S. Grossman, L. Swinnen, 2019, Journal of Neuro-Oncology.

Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study

R. Varadhan, C. Huff, Richard J. Jones, 2022, Leukemia & lymphoma.

Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen

C. Huff, Richard J. Jones, B. Smith, 2009, Bone Marrow Transplantation.

Primary central nervous system lymphoma: recent progress, many remaining questions

L. Swinnen, 2009, Current opinion in oncology.

Allogeneic Blood or Marrow Transplantation with Post-transplantation Cyclophosphamide for Peripheral T-cell Lymphoma: The Importance of Graft Source.

R. Varadhan, C. Huff, Richard J. Jones, 2022, Transplantation and cellular therapy.

Diffuse Large B-Cell Lymphoma Version 1.2016.

J. Byrd, R. Advani, J. Vose, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Flow and image cytometric DNA analysis of postcardiac transplant lymphomas.

S. Fisher, L. Swinnen, J. Walloch, 1994, Modern Pathology.

Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402

R. Gascoyne, T. Habermann, J. Krauss, 2016, British journal of haematology.

Response‐adapted therapy for aggressive non‐Hodgkin's lymphomas based on early [18F] FDG‐PET scanning: ECOG‐ACRIN Cancer Research Group study (E3404)

R. Advani, R. Gascoyne, T. Habermann, 2015, British journal of haematology.

Dose Finding Trial of Yttrium 90 (90Y) Ibritumomab Tiuxetan with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

I. Flinn, R. Wahl, E. Frey, 2004 .

CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease.

M. Gulley, K. Robertson, L. Swinnen, 1996, Blood.

Comparative analysis of the expression of the epstein‐barr virus (EBV) anti‐apoptotic gene BHRF1 in nasopharyngeal carcinoma and EBV‐related lymphoid diseases

M. Gulley, E. Kremmer, J. Nicholls, 2001, Journal of medical virology.

Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404)

R. Advani, R. Gascoyne, T. Habermann, 2012 .

Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.

S. Goodman, R. Wahl, M. Borowitz, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CHOP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial.

J. Manola, R. Advani, T. Habermann, 2009 .

VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY

L. Swinnen, S. Wong, J. Ross, 2017 .

A Rise in CNS Lymphoproliferative Disease Incidence Reveals a Protective Role of Calcineurin Inhibitors

M. Borowitz, L. Swinnen, G. Crane, 2014 .

Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients.

R. Fisher, S. Fisher, L. Swinnen, 1990, The New England journal of medicine.

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Jeffrey A Jones, T. Kipps, L. Swinnen, 2010 .

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Allen R. Chen, M. Zahurak, Richard J. Jones, 2010 .

A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

C. Flowers, L. Swinnen, J. Cordero, 2015 .

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.

J. Byrd, R. Advani, J. Vose, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Sonali M. Smith, J. Friedberg, J. Leonard, 2019, Blood.

Non-Hodgkin's lymphomas.

J. Byrd, R. Advani, J. Vose, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

Shannon R. McCurdy, G. Rosner, C. Huff, 2015, Blood.

Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy.

R. Varadhan, Richard J. Jones, J. Bolaños-Meade, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines.

L. Recht, A. Friedman, M. Gilbert, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder

L. Gordon, R. Fisher, T. Grogan, 2008, Transplantation.

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

R. Advani, J. Vose, A. LaCasce, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.

S. Goodman, R. Wahl, M. Borowitz, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparative analysis of the expression of the epstein‐barr virus (EBV) anti‐apoptotic gene BHRF1 in nasopharyngeal carcinoma and EBV‐related lymphoid diseases

M. Gulley, E. Kremmer, J. Nicholls, 2001, Journal of medical virology.

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.

R. Advani, A. LaCasce, A. Zelenetz, 2023, The Journal of the National Comprehensive Cancer Network.

Dose finding trial of Yttrium 90 ibritumomab tiuxetan (90YIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

I. Flinn, R. Wahl, E. Frey, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI)

Shannon R. McCurdy, C. Huff, Richard J. Jones, 2014 .

Updates to the NCCN Guidelines

A. Krishnan, S. Singhal, C. Huff, 2013 .

Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.

I. Flinn, C. Huff, Richard J. Jones, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Response‐adapted therapy for aggressive non‐Hodgkin's lymphomas based on early [18F] FDG‐PET scanning: ECOG‐ACRIN Cancer Research Group study (E3404)

R. Advani, R. Gascoyne, T. Habermann, 2015, British journal of haematology.